HomeItamar Medical Ltd.

Itamar Medical Ltd.

Mount Sinai Health System NYC: CPAP/COVID Funded by Itamar Medical

The study is a prospective, single-center, parallel-group, open-label, randomized clinical trial to assess the efficacy of CPAP in 200 COVID-19 confirmed or suspected patients within the Mount Sinai Health System with respiratory symptoms who do not require hospital admission and are discharged home from the emergency room.

Publication of COMPASS Study Validating First Scoring Guidelines for WatchPAT™ Device in Diagnosing Sleep Apnea

The study appears online in the Journal of Clinical Sleep Medicine.

Itamar Medical Selected to Participate in the Prestigious Weizmann Institute Project 10K

WatchPAT has been selected for inclusion in the Weizmann Institute’s Project 10K. 

WatchPAT™ One, the First and Only Fully Disposable Home Sleep Apnea Test Receives FDA 510(k) Clearance

WatchPAT™ One technology and the first and only fully disposable Home Sleep Apnea Test (HSAT). WatchPAT One incorporates the technology and comfort advances of WatchPAT 300, which received 510(k) clearance in August 2018 and was launched in March 2019.

Itamar Medical Launches WatchPAT 300

3/20/19: WatchPAT 300 includes several advances that are designed to enhance both patients’ WatchPAT experience as well as provide physicians with a trusted and cost-effective method for rapid, scalable and effective diagnosis of sleep apnea.

Itamar Medical Announces Definitive Agreements for $11.5 Million Private Placement

1/17/19: Net proceeds of the financing will be used primarily to accelerate the Company’s revenue growth through direct expansion of its sales and marketing initiatives.

Itamar Medical Announces Favorable CMS Reimbursement Decision to its WatchPAT™ Sleep Apnea Testing Device

11/9/18: The company announced the release of the 2019 Fee Schedule from the U.S. Centers for Medicare & Medicaid Services (CMS) that should support broad use of its WatchPAT technology.